|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for ANGPT2 |
 Gene summary |
| Basic gene Info. | Gene symbol | ANGPT2 |
| Gene name | angiopoietin 2 | |
| Synonyms | AGPT2|ANG2 | |
| Cytomap | UCSC genome browser: 8p23.1 | |
| Type of gene | protein-coding | |
| RefGenes | NM_001118887.1, NM_001118888.1,NM_001147.2, | |
| Description | ANG-2Tie2-ligandangiopoietin-2angiopoietin-2Bangiopoietin-2a | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 601922 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000091879 | ||
| HPRD : 03563 | ||
| Vega : OTTHUMG00000090365 | ||
| Protein | UniProt: O15123 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_ANGPT2 | |
| BioGPS: 285 | ||
| Pathway | NCI Pathway Interaction Database: ANGPT2 | |
| KEGG: ANGPT2 | ||
| REACTOME: ANGPT2 | ||
| Pathway Commons: ANGPT2 | ||
| Context | iHOP: ANGPT2 | |
| ligand binding site mutation search in PubMed: ANGPT2 | ||
| UCL Cancer Institute: ANGPT2 | ||
| Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID | GO:0043537 | negative regulation of blood vessel endothelial cell migration | 9660821 | GO:0048014 | Tie signaling pathway | 19922791 | GO:0050928 | negative regulation of positive chemotaxis | 9660821 |
| Top |
| Ligand binding site mutations for ANGPT2 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | D429 | G428R | LUAD | 1 | I434 | I434L | UCEC | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for ANGPT2 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | D429 | G428R | -1.2165154 | I434 | I434L | -0.96284474 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for ANGPT2 from PDB |
| Top |
| Differential gene expression and gene-gene network for ANGPT2 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for ANGPT2 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| umls:C0018923 | Hemangiosarcoma | 1 | Biomarker |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for ANGPT2 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of ANGPT2 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | CA | CALCIUM(2+) | 1z3u | C | D429 | CA | CALCIUM(2+) | 1z3u | D | D429 | CA | CALCIUM(2+) | 2gy7 | A | D429 | CA | CALCIUM(2+) | 1z3s | A | D429 I434 | CA | CALCIUM(2+) | 1z3s | B | D429 I434 | CA | CALCIUM(2+) | 1z3u | A | D429 I434 | CA | CALCIUM(2+) | 1z3u | B | D429 I434 | CA | CALCIUM(2+) | 4zfg | A | D429 I434 |
| Top |
| Conservation information for LBS of ANGPT2 |
| Multiple alignments for O15123 in multiple species |
| LBS | AA sequence | # species | Species | C433 | SDNDKCICKCS | 2 | Mus musculus, Rattus norvegicus | C433 | ADNDKCICKCS | 2 | Bos taurus, Canis lupus familiaris | C433 | GDNDKCICKCS | 1 | Homo sapiens | C435 | NDKCICKCSQM | 5 | Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus, Canis lupus familiaris | D429 | STKDSDNDKCI | 2 | Mus musculus, Rattus norvegicus | D429 | STKDADNDKCI | 2 | Bos taurus, Canis lupus familiaris | D429 | STKDGDNDKCI | 1 | Homo sapiens | D431 | KDSDNDKCICK | 2 | Mus musculus, Rattus norvegicus | D431 | KDADNDKCICK | 2 | Bos taurus, Canis lupus familiaris | D431 | KDGDNDKCICK | 1 | Homo sapiens | I434 | DNDKCICKCSQ | 5 | Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus, Canis lupus familiaris | K436 | DKCICKCSQML | 5 | Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus, Canis lupus familiaris |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |